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Abstract: Purpose: Gynecologic Cancer Intergroup Symptom Benefit Study (GCIG-SBS) Stage 2
aimed to review, revise then validate the Measure of Ovarian Symptoms and
Treatment concerns (MOST), developed in GCIG-SBS Stage 1 (MOSTv1, 35 items),
and comprehensively document ROC symptom burden and benefit.
Methods:  GCIG-SBS Stage 2 recruited patients with platinum resistant/refractory
recurrent ovarian cancer (PRR-ROC) or potentially platinum sensitive ROC with ≥3
lines of prior chemotherapy (PPS-ROC≥3).  Patients completed MOSTv1, QLQ-OV28
and FACT-O/FOSI at baseline and before cycle 3 of chemotherapy (pre-C3), and
global assessments of change (MOST-Change) pre-C3.  Clinicians rated patients'
cancer-related symptoms, performance status and adverse events. Internal
consistency (Cronbach's alpha), convergent and divergent validity (Spearman
correlations), discriminative validity (effect sizes between groups classified by clinician-
rated characteristics) and responsiveness (paired t-tests in patients expected to
experience clinically meaningful change) were assessed.
Results: Of 948 recruits, 903 completed PROMs at baseline and 685 pre-C3. Baseline
symptom burden was substantial, with few differences between PRR-ROC and PPS-
ROC≥3.  Eleven MOSTv1 items were excluded. MOSTv2 has 24 items and five multi-
item scales: abdominal symptoms (MOST-Abdo), disease or treatment-related
symptoms (MOST-DorT), chemotherapy-related symptoms (MOST-Chemo),
psychological symptoms (MOST-Psych), and MOST-Wellbeing. Cronbach's alpha
were >0.80. Correlations confirmed concurrent and divergent validity. Discriminative
validity was confirmed by effect sizes that conformed with a priori hypotheses. MOST-
Abdo was responsive to improvements in abdominal symptoms and MOST-Chemo
detected the adverse effects of chemotherapy.
Conclusions:  The MOSTv2 validly quantifies patient-reported symptom burden,
adverse effects, and symptom benefit in ROC, making fit-for-purpose for clinical trials
of palliative chemotherapy in ROC.
Suggested Reviewers: Richard T Penson, MD, MRCP
Clinical Director, Medical Gynecologic Oncology, Massachusetts General Hospital
rpenson@partners.org
Dr Penson is a medical oncologist with interests in gynecologic oncology and
psychosocial oncology, who treats patients with ovarian cancer. Clinician researcher
involved in Gynecologic Oncology Group (GOG) studies, with a particular interest and
involvement in HRQOL endpoints and analysis.
Ethan Basch, MD, MSC
Director, Cancer Outcomes Research Program, University of North Carolina
Lineberger Comprehensive Cancer Center
ebasch@med.unc.edu
Dr. Basch is a medical oncologist and health services researcher.  His clinical expertise
is prostate cancer, and his research expertise includes patient-reported outcomes,
drug regulatory policy, and comparative effectiveness research.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Measuring what matters MOST: validation of the 
Measure of Ovarian Symptoms and Treatment, a 
patient-reported outcome measure of symptom 
burden and impact of chemotherapy in recurrent 
ovarian cancer 
 
Madeleine T King , Martin R Stockler, Rachel L. O’Connell, Luke Buizen, Florence Joly, Anne 
Lanceley, Felix Hilpert, Aikou Okamoto, Eriko Aotani, Jane Bryce, Paul Donnellan, Amit Oza, 
Elisabeth Avall-Lundqvist, Jonathan Berek, Jalid Sehouli, Mandy Feeney, Dominique Berton-
Rigaud, and Michael Friedlander; for the GCIG Symptom Benefit group 
 
Madeleine King, University of Sydney, Sydney, NSW, Australia; Australia New Zealand 
Gynaecological Oncology Group (ANZGOG) 
Martin Stockler, National Health and Medical Research Council (NHMRC) Clinical Trials 
Centre, University of Sydney, Sydney, NSW, Australia; Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) 
Rachel O'Connell, National Health and Medical Research Council (NHMRC) Clinical Trials 
Centre, University of Sydney, Sydney, Australia 
Luke Buizen, National Health and Medical Research Council (NHMRC) Clinical Trials Centre, 
University of Sydney, Sydney, Australia 
Florence Joly, Centre Francois Baclesse, Caen, France; Group d’Investigateurs Nationaux 
pour l’Etude des Cancers Ovariens (GINECO) 
Anne Lanceley, University College London, London, United Kingdom; National Cancer 
Research Institute (NCRI); Medical Research Council Clinical Trials Unit (MRC CTU) 
Felix Hilpert, Onkologisches Therapiezentrum am Krankenhaus Jerusalem Hamburg, 
Hamburg, Germany; Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe (AGO 
Study Group) 
Aikou Okamoto, Jikei University School of Medicine, Tokyo, Japan; Japanese Gynecologic 
Oncology Group (JGOG) 
Eriko Aotani, Global Health Research Coordinating Center, Kanagawa Academy of Science 
and Technology, Kanagawa, Japan; Gynecologic Oncology Trial and Investigation Consortium 
(GOTIC) 
Jane Bryce, National Cancer Institute, Naples, Italy; Multicenter Italian Trials in Ovarian 
cancer and gynecologic malignancies group (MITO) 
Title page
Paul Donnellan, Cancer Trials Ireland, Galway University Hospital, Galway, Ireland; All Ireland 
Cooperative Oncology Research Group (ICORG) 
Amit Oza, Princess Margaret Hospital, Toronto, Canada; Princess Margaret Consortium 
(PMHC) 
Elisabeth Avall-Lundqvist, Linkoping University, NSGO, Linkoping, Sweden; Nordic Society of 
Gynaecological Oncology (NSGO) 
Jonathan Berek, Stanford Comprehensive Cancer Institute, Stanford, CA, United States; 
Cooperative Ovarian Cancer Group (COGi) 
Amanda Feeney, University College London, London, United Kingdom; National Cancer 
Research Institute (NCRI); Medical Research Council Clinical Trials Unit (MRC CTU) 
Dominique Berton-Rigaud, Institut de Cancerologie de l’Ouest (ICO), Centre René 
Gauducheau, Saint Herblain, France; Group d’Investigateurs Nationaux pour l’Etude des 
Cancers Ovariens (GINECO) 
Jalid Sehouli, Department of Gynecology and Oncological Surgery, Charité, University of 
Berlin, Germany; Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe (AGO Study 
Group) 
Michael Friedlander, Prince of Wales Hospital, Sydney, Australia; Australia New Zealand 
Gynaecological Oncology Group (ANZGOG) 
On behalf of the GCIG Symptom Benefit Study Group, Gynecologic Cancer Intergroup (GCIG), 
Kingston, Ontario, Canada. 
 
Corresponding author: 
Madeleine King 
Quality of Life Office, Psycho-oncology Co-operative Research Group 
Level 6 North, Chris O’Brien Lifehouse C39Z 
University of Sydney NSW 2006 Australia 
E-mail: madeleine.king@sydney.edu.au 
P: +612 434 164 438 
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms 
and Treatment, a patient-reported outcome measure of symptom burden and 
impact of chemotherapy in recurrent ovarian cancer 
 
ABSTRACT  (250 of 250 word limit) 
 
Purpose: Gynecologic Cancer Intergroup Symptom Benefit Study (GCIG-SBS) Stage 2 aimed 
to review, revise then validate the Measure of Ovarian Symptoms and Treatment concerns 
(MOST), developed in GCIG-SBS Stage 1 (MOSTv1, 35 items), and comprehensively 
document ROC symptom burden and benefit. 
 
Methods:  GCIG-SBS Stage 2 recruited patients with platinum resistant/refractory recurrent 
ovarian cancer (PRR-ROC) or potentially platinum sensitive ROC with ≥3 lines of prior 
chemotherapy (PPS-ROC≥3).  Patients completed MOSTv1, QLQ-OV28 and FACT-O/FOSI at 
baseline and before cycle 3 of chemotherapy (pre-C3), and global assessments of change 
(MOST-Change) pre-C3.  Clinicians rated patients’ cancer-related symptoms, performance 
status and adverse events. Internal consistency (Cronbach’s alpha), convergent and 
divergent validity (Spearman correlations), discriminative validity (effect sizes between 
groups classified by clinician-rated characteristics) and responsiveness (paired t-tests in 
patients expected to experience clinically meaningful change) were assessed. 
 
Results: Of 948 recruits, 903 completed PROMs at baseline and 685 pre-C3. Baseline 
symptom burden was substantial, with few differences between PRR-ROC and PPS-ROC≥3.  
Eleven MOSTv1 items were excluded. MOSTv2 has 24 items and five multi-item scales: 
abdominal symptoms (MOST-Abdo), disease or treatment-related symptoms (MOST-DorT), 
chemotherapy-related symptoms (MOST-Chemo), psychological symptoms (MOST-Psych), 
and MOST-Wellbeing. Cronbach’s alpha were >0.80. Correlations confirmed concurrent and 
divergent validity. Discriminative validity was confirmed by effect sizes that conformed with 
a priori hypotheses. MOST-Abdo was responsive to improvements in abdominal symptoms 
and MOST-Chemo detected the adverse effects of chemotherapy.   
 
Conclusions:  The MOSTv2 validly quantifies patient-reported symptom burden, adverse 
effects, and symptom benefit in ROC, making it fit-for-purpose for clinical trials of palliative 
chemotherapy in ROC. 
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Introduction  
 
Recurrent ovarian cancer (ROC) – what’s the problem? 
The goals of treatment for recurrent ovarian cancer (ROC) are to reduce disease-related 
symptoms, delay disease progression, and prolong overall survival. Yet in clinical trials, the main 
metrics used to measure the benefit of palliative chemotherapy and for regulatory approval of 
drugs are overall survival and progression-free survival are. Trials rarely assess or document the 
overall symptom burden, the proportion of patients with specific cancer-related symptoms, or 
the extent to which symptoms improve with palliative chemotherapy. The burden of cancer-
related symptoms, and their relief, should be key considerations for patients, clinicians, 
regulators, and policy makers. 
Women with ROC are a heterogeneous group with highly variable time to progression. Disease 
relapsing later than 6 months after first-line platinum-based chemotherapy is classified platinum 
sensitive, tumour response rates are 25% to 67%, and median survival 2 to 3 years [1]. Disease 
progressing earlier is classified platinum resistant, with tumour response rates of 10% to 15%, 
and median survival 9 to 12 months [2]. Disease progressing during chemotherapy is classified 
as platinum refractory, and has response rates of 10% or less and median survival <6 months 
with chemotherapy [2]. The benefits of chemotherapy diminish with each successive line [3]: in 
a retrospective analysis of over 1600 patients, the median progression-free survival after first, 
second, and third treated recurrences was 10, 6, and 4 months, respectively [3]. 
 The 3rd Ovarian Cancer Consensus Conference recognized the importance of symptom benefit 
as an endpoint for clinical trials, and recommended development and validation of an 
instrument to measure this in women with ROC, particularly those with platinum resistant-
Manuscript Click here to download Manuscript MOST-Validation-MWM-
FINAL.docx
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refractory ovarian cancer (PRROC) [4]. This led to the symptom benefit working group of the 
Gynecologic Cancer Intergroup (GCIG) and, subsequently, the two-stage Symptom Benefit Study 
(GCIG-SBS). More recently, the European Society of Medical Oncology (ESMO) and American 
Society of Clinical Oncology (ASCO) have proposed standardized measures of the magnitude of 
clinical benefit [5] and the net health benefit [6] in clinical trials that incorporate effects on 
survival time, toxicity, and health-related quality of life to determine whether patients are living 
better and/or longer as a result of their anticancer treatment. The aims and objectives of GCIG-
SBS were closely aligned with these recommendations. 
GCIG-SBS Stage 1: developing MOST version 1 (MOSTv1) 
The primary aim of GCIC-SBS Stage 1 was to document the most prevalent symptoms in women 
with PRROC (expected to result in the greatest symptom burden), and to seek an optimal 
instrument to measure subjective symptom benefit in clinical trials of palliative chemotherapy 
[7, 8]. We defined “optimal” as best able to provide efficient and focused measurement of 
symptom benefit as an endpoint in clinical trials, then operationalized this with four criteria 
derived from key elements of the Food and Drug Administration’s (FDA) recommended process 
for developing a patient-related outcome measure (PROM): content validity, recall period, item 
rating scale, and scoring [9]. We used mixed methods to identify the symptoms that were most 
noticed and most severe in the Stage 1 sample of 129 women [8], then assessed the extent to 
which these were covered by existing candidate PROMs. While the EORTC QLQ-C30 [10] and 
QLQ-OV28 [11] together cover all of these symptoms, their scoring algorithms split them into 
numerous scales, potentially dissipating effects, and requiring multiple testing when analyzing 
them for clinical trials. The FACT-O [12] covered all but two of the most prevalent cancer-related 
symptoms, but combined these with chemotherapy side-effects and other aspects of health-
related quality of life, leading to potential dilution in multi-item summary scales. This was partly 
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addressed by the development of two FACT Ovarian Symptom Indexes (FOSI) [13-15], but even 
these are somewhat diluted by other issues, including preexisting adverse effects of 
chemotherapy and existential concerns that are unlikely to improve with chemotherapy. 
Further, the recall period for those PROMs is a week, while the period between chemotherapy 
cycles is typically 3-4 weeks. We therefore undertook to develop a new PROM to quantify the 
overall symptom burden, the benefit of chemotherapy, and the adverse effects of 
chemotherapy: the Measure of Ovarian Symptoms and Treatment concerns (MOST). 
Steps in developing the MOST 
In developing and validating the MOST, we followed the iterative process recommended by the 
FDA for developing a PROM [9], which comprises five steps. Stage 1 of the GCIG-SBS addressed 
the first two of these steps by developing a conceptual framework, and then drafting the 
MOSTv1 with patient input, piloting the MOSTv1, and determining its content validity (step 2) 
[8]. In this paper, we complete step 2 by assessing adjustments to our conceptual framework, 
and address step 3 using data collected in Stage 2 of the GCIG-SBS.  
GCIG-SBS Stage 2: Aims 
The main aims of GCIG-SBS Stage 2 were: 1. to confirm the MOST’s final conceptual framework 
with scoring rules; 2. to assess the reliability of component scores; 3. to assess the ability of 
component scores to detect changes; and, 4. to comprehensively document the symptoms most 
prevalent in ROC at baseline. 
Methods 
GCIG-SBS Stage 2 study design, participants and data collection 
This prospective, observational cohort study recruited women with PRROC and women with 
potentially platinum-sensitive ovarian cancer who had had three or more lines of chemotherapy 
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(PPS≥3) from 120 sites in 11 countries. Eligibility criteria were: ROC and; progression based on 
CA125 level, imaging, or clinical characteristics; Eastern Cooperative Oncology Group 
performance status 0 to 3; life expectancy >3 months; and ability to complete questionnaires 
independently. Chemotherapy and supportive care were at the discretion of treating physicians. 
Treating physicians recorded their patients’ baseline characteristics and the presence of ascites, 
cramping abdominal pain or intermittent or incomplete bowel obstruction. They assessed 
‘clinical benefit’ every 6–8 weeks (2–3 cycles of chemotherapy) according to CA125, RECIST, 
and/or symptomatic improvement. PROMs included the MOSTv1 [8], EORTC QLQ-C30 [10], QLQ-
OV28 [11], FACT-O [12], and FOSI [13-15]. Participants completed these PROMs at baseline 
(before their first cycle of chemotherapy), then every 3 to 4 weeks before chemotherapy, until 
disease progression. Participants completed the MOST-Change questionnaire 3–4 weeks after 
their second cycle of chemotherapy, immediately before cycle 3. This time point was chosen 
because any improvement in cancer-related symptoms due to chemotherapy (symptom benefit) 
was judged likely to be evident by then, and many patients stop chemotherapy after two cycles 
because of progression [16]. This corresponded with the first assessment of clinical benefit by 
the treating physician. The MOST-Change questionnaire asks participants for each aspect 
included in the MOSTv1, ‘how things are now, compared with how things were before you 
started this course of chemotherapy 6–8 weeks ago, rated on a 5-point scale: much better, a 
little better, the same, a little worse, or much worse. 
The MOSTv1 and MOST-Change questionnaires were provided in English, German, French, 
Italian, Japanese, Swedish after translation from English, based on the EORTC guidelines [17]. 
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PROM development steps 2 and 3: review conceptual framework, content and scoring rules 
Our initial conceptual framework (GCIG-SBS Stage 1, PROM development step 1) envisaged two 
indexes: one assessing disease-related symptoms, the other treatment-related concerns, so that 
the benefits and burdens of chemotherapy could be quantified separately. On reflection, this 
was an oversimplification, and we revised our conceptual framework into four groups of 
symptoms plus a global wellbeing group: 
 Physical symptoms most likely due to ROC and not chemotherapy; 
 Physical symptoms most likely due to chemotherapy and not ROC; 
 Physical symptoms reasonably likely due to ROC and/or chemotherapy; 
 Psychological symptoms; 
 Global wellbeing (physical, emotional and overall). 
Our approach remained predominantly clinimetric rather than psychometric [18], i.e. our goal 
was indexes to include key symptoms according to their likely causes, regardless of their co-
occurrence and/or correlations. 
Our guiding principle was to measure what matters and no more. We therefore excluded items 
that: 
  had low prevalence at baseline and pre-cycle 3 and did not change markedly over time; 
 were conceptually and/or functionally similar, and highly correlated (≥0.50) with an already 
included item; 
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 were symptoms of neither ROC nor chemotherapy (other existing PROMs in the EORTC and 
FACIT suites address these aspect of health-related quality of life). 
As an evidence base for our PROM development considerations, and to address our objective of 
comprehensively documenting the symptoms most prevalent in ROC at baseline, we 
summarized the prevalence of each MOSTv1 item at baseline and pre-C3 with its mean, 
standard deviation, and proportions based on the MOST response format, a numeric rating scale 
with integers from zero to 10, with five verbal anchors: ‘No trouble at all’ (over 0), ‘Mild’ (over 
1–3), ‘Moderate’ (over 4–6), ‘Severe’ (over 7–10), and ‘Worst I can imagine’ (over 10). We used 
chi-squared tests to assess differences in baseline symptoms between PRROC and PPS≥3. 
Associations between items were assessed at baseline and pre-C3 using Spearman’s rank 
correlations (rs). 
A key requirement for using the MOST in clinical trials is to have scoring rules yielding PROM 
scales that are sensitive to both improvement (symptom benefit) and deterioration (burden of 
treatment and/or worsening of disease). To achieve this, we sought items that changed in the 
same direction (either all improved or all worsened) and assessed mean changes from baseline 
to pre-C3. On the basis of these considerations, multi-item symptom scales were scored by 
taking the average of the component items, with linear rescaling to an observable range of 0–
100, with higher scores representing worse symptoms or better wellbeing. 
Psychometric properties 
Reliability: Given our clinimetric approach, we did expect or require high internal consistency 
between items within each multi-item scale [19], but nevertheless assessed it with Cronbach’s 
alpha. 
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Construct validity: We assessed evidence that relationships among items, multi-item scales and 
concepts conformed to a priori hypotheses concerning logical relationships that should exist 
with other measures or patient characteristics, as follows. 
Convergent and divergent validity: we hypothesized that the MOST multi-item scales should be 
strongly correlated (r=0.50 or higher, Cohen’s threshold for strong correlation [20]) with related 
scales from the EORTC QLQ-C30/OV28, FACT-O and FOSI, and more strongly correlated with 
these scales than with other scales of the MOST and other PROMS that measured less related 
constructs [21]. 
Discriminative validity (difference between ‘known groups’): We hypothesized the MOST would 
discriminate between clinically distinct groups, as specified in the following five hypotheses (H1–
H5).  
H1. Baseline MOST scores for physical symptoms of ROC would be worse for participants rated 
by clinicians at baseline as having cancer-related symptoms, ascites, abdominal 
pain/obstructive symptoms, or poor performance status (ECOG PS 2–3 versus 0–1), than for 
those not having these characteristics. 
H2. Patterns for baseline wellbeing would be similar to those for H1, but with smaller gradients 
than for self-reported physical symptoms, because wellbeing is less directly related to these 
clinical characteristics. 
H3.  Psychological symptoms were not expected to differ according to clinicians’ ratings of 
ascites, abdominal pain/obstructive symptoms, or performance status, as observed 
previously for the QLQ-C30 [22, 23]. 
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H4. At pre-C3, patient self-report of specific symptoms, on average, would increase in a 
gradient across CTC-AE grades for analogous National Cancer Institute Common 
Terminology for Adverse Events (CTC-AE v4) symptoms. 
H5. At pre-C3, MOST multi-item scales rating symptoms that may be caused by chemotherapy 
would be worse (higher) for participants with CTC-AE grades higher than the median. 
For MOST multi-item scales, we assessed H1-H5 with mean differences, independent t tests and 
Cohen’s D effect sizes, defined as the mean difference divided by its standard deviation [20], 
and 95% confidence intervals (CI). All scores were transformed using the square root function to 
achieve normality for the t test and calculation of Cohen's D. For MOSTv1 items that had a 
corresponding CTC-AE item, the Kruskall-Wallis test was used to test for differences in MOST 
ranks across CTC-AE grades, and gradients were assessed visually in boxplots. 
Longitudinal validity (Responsiveness to expected change): We hypothesized that changes in 
MOST multi-item scale scores from baseline to pre-C3 would follow a gradient from most 
improved through to most worsened when grouped by patients’ global ratings of change on 
conceptually-related MOST-Change items with correlations ≥0.30 [24]. We assessed this 
statistically with analysis of variance (ANOVA) and visually with boxplots. 
We hypothesized that a MOST multi-item scale composed of physical symptoms most likely due 
to ROC and not chemotherapy would register an improvement with chemotherapy in women 
whose treating clinicians recorded baseline cramping abdominal pain or 
intermittent/incomplete bowel obstruction, and that this improvement would be most apparent 
in the subgroup who rated their overall wellbeing as much better on the MOST-Change 
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questionnaire at pre-C3. We hypothesized similar but larger effects when the patient-report of 
abdominal symptoms was used to define the group baseline burden and pre-C3 benefit. 
We hypothesized that a MOST scale comprising physical symptoms most likely due to 
chemotherapy and not ROC would register the known toxic impact of chemotherapy, i.e. an 
increase from baseline to pre-C3, more so for PPS≥3 than for PRROC, as the former received 
combination chemotherapy while the latter received single-agent chemotherapy. 
Statistical analyses were conducted in SAS and STATA. 
Results  
 
Stage 2 of GCIG-SBS recruited 948 participants including 903 (96%) who completed the MOSTv1 
at baseline (Table 1) and 685 (72%) who completed MOSTv1 and MOST-Change pre-C3. Missing 
data rates for MOST items were low (0.8–3.5% at baseline, 0.3–5.1% at pre-C3). 
Symptom burden at baseline 
Baseline symptom burden was substantial (Figure 1), with little difference between patients 
with PRROC versus PPS≥3 (p>0.05 for all items except vomiting (p=0.03, 21% PRROC mild 
or moderate vs 13% PPS≥3) and hair loss (p=0.003, 22% PRROC moderate or severe vs 
12%  PPS≥3)). Most participants (86%) reported one or more symptoms as moderate or severe 
(MOST item score of 4–10), 50% reported 6 or more symptoms moderate or severe, and 27% 
reported 9 or more symptoms as moderate or severe. The most common and severe symptoms 
were abdominal, fatigue, anorexia and anxiety. The items for ‘abdominal swelling, bloating 
and/or fullness’ (MOSTv1 item 4) and for ‘abdominal pain, discomfort, and/or cramps’ (MOSTv1 
item 5) often co-occurred: either or both were reported as severe by 28% of participants, 
moderate by 26%, mild by 31%, and no trouble at all by 15%. 
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Impact of chemotherapy 
Among the 685 women who provided ratings at baseline and pre-C3, the symptoms that 
improved most (P<0.001) were: abdominal swelling, bloating, and/or fullness; abdominal pain, 
discomfort and/or cramps; and anxiety (Figure 2). Each improved on average by about half a 
point on the 0–10 point MOST item response scale. Of the seven symptoms that worsened most 
(P<0.001), four were due to chemotherapy (hair loss, altered sense of taste, sore mouth or 
throat, skin rash) and three to cancer or chemotherapy (fatigue, nausea, and difficulty 
swallowing). 
Revision of conceptual framework, content and scoring rules: from MOSTv1 to MOSTv2 
In our revisions of the MOSTv1 conceptual framework, content and scoring rules, 11 items were 
excluded (3 deemed redundant because they were conceptually and empirically related to 
retained items and 7 judged to be consequences rather than symptoms of ROC) (Table 2). ‘Pain 
(all/anywhere)’ and ‘trouble concentrating’ were judged too general, and could be due to other 
causes. 
For MOSTv2, we proposed scoring rules that aggregated the 24 items retained into five multi-
item scales: abdominal symptoms (MOST-Abdo), disease or treatment-related symptoms 
(MOST-DorT), chemotherapy-related symptoms (MOST-Chemo), psychological symptoms 
(MOST-Psych), and wellbeing (MOST-Wellbeing). Nine items that could be caused by either 
disease or treatment worsened on average from baseline to pre-C3, while two improved 
(‘trouble sleeping’, ‘bladder problems’). We assessed 9 and 11 item versions (MOST-DorT-9, 
MOST-DorT-11), as it was unclear how ‘trouble sleeping’ and ‘bladder problems’ would affect 
the MOST-DorT scale’s performance. 
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Psychometric properties 
Internal consistency was excellent for all MOSTv2 multi-item scales (Cronbach’s alpha ≥ 0.80) 
except MOST-DorT-11 (alpha<0.70) at baseline (Table 3) and pre-C3 (Table A, online resource). 
Convergent and divergent validity were confirmed at baseline (Table 3) and pre-C3 (Table A, 
online resource). Each MOSTv2 multi-item scale substantially correlated with similar scales from 
other PROMs (rs always >0.50, often ≥0.70), and typically this correlation was the highest of all 
correlations for that MOST scale. MOST-Abdo and MOST-DorT were always correlated >0.60 
with FOSI-8 and FOSI-15, while MOST-Chemo correlated <0.50, and the correlation for MOST-
Psych increased from about 0.5 at baseline to ≥0.60 pre-C3. Correlations among MOST scales 
were highest between MOST-Abdo and MOST-DorT (about 0.7), lowest with MOST-Chemo 
(0.25-0.52) and MOST-Psych (0.25-0.56), and generally increased from baseline to pre-C3. 
Discriminative validity was confirmed (Table 4). Effect sizes for MOST-Abdo were larger for 
participants classified by clinician-rated symptoms than by clinician-rated performance status, 
and vice versa for MOST-Wellbeing. Effect sizes for MOST-DorT were smallest for clinician-rated 
abdominal pain/bowel obstruction (reflecting least similarity of content) and CTC-AE at baseline 
(reflecting low toxicity burden at baseline), with larger effect sizes pre-C3, reflecting the increase 
in toxicity burden for the MOST-DorT symptoms. Expected gradients were observed in the 
distributions of MOST items scores across CTC-AE grades for the 11 symptoms with comparable 
CTC-AE items (Figures A and B, online resource). 
Longitudinal validity: Figure 3 shows a clear gradient for MOST-Abdo (grouped by the average of 
the two abdominal symptom items on the MOST-Change form, r=0.41), MOST-DorT-9 and -11 
(grouped by the physical wellbeing change item, item r=0.39, 0.40), and MOST-Wellbeing 
(grouped by the overall wellbeing change item, item r=-0.36). Correlations for MOST-Psych and 
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the emotional wellbeing change item (r= 0.25) and MOST-Chemo and the physical wellbeing 
change item (r= 0.22) were less than the required 0.30 threshold. The MOST-Change scores at 
pre-C3 explained a significant proportion of the change from baseline to pre-C3 in all MOST 
multi-item scores (all P<0.001, ANOVA). 
Responsiveness: The MOST-Abdo scale was responsive to expected improvements with 
chemotherapy among patients recorded to have symptoms of cramping abdominal pain or 
intermittent/incomplete bowel obstruction at baseline (Table 5), and very responsive in 
subgroups expected to show improvements (Table 6), more so for the patient-based than the 
clinician-based definition. The MOST-Chemo scale was responsive to expected deteriorations 
due to chemotherapy toxicity, registering the expected changes from baseline to pre-C3, more 
so for women with PPS≥3 (predominantly treated with combination chemotherapy) than with 
PRROC (predominantly treated with single-agent chemotherapy) (Table 5). 
Results for the other MOST multi-item scales presented in Table 5 demonstrate their clinical 
utility in describing the symptom benefit of chemotherapy and toxicity burden, for participants 
who were symptomatic versus asymptomatic, and with PRROC versus PPS≥3. 
Discussion 
These results from a large, international initiative focusing on symptom burden, treatment 
benefit, and treatment toxicity in ROC complete steps 2 and 3 of the iterative process 
recommended by the FDA for developing PROMs, by adjusting the conceptual framework of the 
MOST, confirming it with scoring rules, and assessing the reliability, validity and responsiveness 
of resultant multi-item scales. The MOSTv2 contains 24 items and yields five multi-item scales: 
MOST-Abdo, MOST-DorT, MOST-Chemo, MOST-Psych, MOST-Wellbeing. All scales have 
excellent internal consistency, except the MOST-DorT 11-item version. Convergent and 
  21-Nov-16 13 
divergent validity were confirmed for all scales. Discriminant validity was confirmed for all scales 
except the MOST-Psych, for which we lacked a suitable clinical anchor. The MOST’s ability to 
detect clinically important changes was demonstrated. The responsiveness of the MOST-Abdo to 
improvements in the abdominal symptoms of ROC makes it a good candidate as a key endpoint 
in trials of palliative chemotherapy for ROC, as these are the defining and predominant 
symptoms of ROC. The MOST-Chemo detected the adverse effects of chemotherapy and specific 
toxicities. 
Some symptoms of ROC may be caused by both the cancer and its treatment - this is the most 
challenging aspect of the impact of chemotherapy to measure and interpret. The MOST-DorT 
increased (worsened) with chemotherapy in asymptomatic participants, and we surmise that 
this was predominantly because of the adverse effects of chemotherapy. Similarly, we surmise 
that the larger increase in MOST-DorT for PPS≥3 versus PRROC was also because of the greater 
adverse effects of multi-agent chemotherapy compared with a single agent. We have reported 
two versions of the MOST-DorT—with and without ‘trouble sleeping’ and ‘bladder problems’—
as these were the only two symptoms due to disease or treatment that improved with 
chemotherapy. While this may be a sample-specific finding, reduction of abdominal bloating 
should reduce bladder symptoms, and this along with reduced anxiety and pain could improve 
sleeping. We did not show substantial differences in the performance of these two versions, 
except that the 11-item version lacked internal consistency. Further comparisons in other 
datasets are required to determine whether these two items should be reported as single items 
or combined with the other nine symptoms of disease or treatment. 
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We have also addressed the secondary aim of Stage 2 of the GCIG-SBS, by comprehensively 
documenting the symptom burden of ROC before chemotherapy, and further, have used MOST 
to estimate the impact of chemotherapy in terms of benefits and harms in this cohort. 
GCIG-SBS Stage 2 had some limitations for comprehensive validation of MOSTv2. Test-retest 
reliability was not built into the data collection design of the study; this needs to be addressed in 
future studies. We lacked suitable anchors for assessing the MOST-Psych’s discriminative validity 
and responsiveness; future studies that target or identify clinical cases of anxiety and depression 
are required. The use of clinician-rated CTC-AEs was somewhat limited for MOST-Chemo 
validation because of differences between the patient-rated and clinician-rated items in the 
specification of symptoms [25]. 
 Although thousands of women with ROC have participated in clinical trials of palliative 
chemotherapy, whether chemotherapy palliates symptoms is so far unsubstantiated. The 
development of MOST was driven by the imperative for a measure of symptom benefit, in direct 
response to the third consensus conference [4]. The GCIG-SBS illustrates the theory and 
methods of developing and validating a PROM designed to measure what matters most from 
the perspective of patients with ROC. We followed the FDA’s iterative process for developing 
and validating a fit-for-purpose PROM in over 1000 women with ROC who participated in GCIG-
SBS, Stages 1 and 2. MOST is now ready for inclusion in clinical trials of palliative chemotherapy 
in ROC, and will meet the need for symptom benefit to be included as a trial endpoint, as 
identified by the fourth consensus conference [26]. 
About 20% of study participants were reported asymptomatic at baseline, with clinicians stating 
the aim of chemotherapy was to delay the development of symptoms. It is unclear how often 
this is achieved, because the delay in development of cancer-related symptoms has not yet 
  21-Nov-16 15 
been measured in randomized trials. For asymptomatic patients, symptom benefit is not 
relevant and yet treatment toxicity is likely; chemotherapy cannot make these patients feel 
better but it will probably make them feel worse. This clinically important postulation should be 
addressed in future clinical trials, and could be assessed with MOST. 
This study clearly demonstrates the substantial baseline symptom burden reported by patients 
with ROC: 86% reported at least one of the MOST symptoms as moderate or severe, 50% rated 6 
or more symptoms moderate or severe, and 27% rated 9 or more symptoms moderate or 
severe. These findings underscore the importance of documenting the severity of symptoms at 
baseline and the effects of treatment on these symptoms. The predominant and disease-
defining symptoms of ROC were ‘abdominal pain, discomfort and/or cramps’; and ‘abdominal 
swelling, bloating and/or fullness’, the symptoms most likely to be improved by chemotherapy. 
These observations suggest that the MOST-Abdo is a suitable endpoint for clinical trials of 
palliative chemotherapy in ROC. 
The MOST is a flexible instrument that can be adapted and modified, depending on the aims and 
objectives of the clinical trial. Symptoms within the MOST-Chemo and MOST-DorT—attributable 
to chemotherapy, or to disease and/or treatment, respectively—may be analyzed separately 
item by item, or together in overall symptom indexes. The preferred options will depend on the 
target population, treatments, and patient-reported outcome hypotheses specified a priori. 
We developed the MOST as a PROM fit for the purpose of assessing the benefit and harms of 
palliative chemotherapy in ROC. We have established key aspects of the MOSTv2’s reliability, 
validity, and responsiveness, and identified evidence gaps for future research. The 24-
item MOSTv2 is designed to take less than 5 minutes to complete, and to provide a 
comprehensive assessment of the burden of symptoms and effects of palliative chemotherapy, 
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both beneficial and adverse, in ROC. MOST focuses exclusively on symptoms and aspects of 
wellbeing; researchers wishing to assess health-related quality of life should use MOST together 
with the EORTC and/or FACIT measures. In conclusion, we are now positioned to meet the ASCO 
and ESMO directive to “measure what matters” in trials of palliative chemotherapy. 
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Table 1. Baseline characteristics of patients who completed at least one item of the MOST questionnaire 
at baseline (n=903) 
Characteristic n (%) 
Age (years, mean 62.5)  
 23–49 103 (11.5) 
 50–59 245 (27.1) 
 60–69 298 (33.0) 
 70–89 257 (28.5) 
Type of resistance, PRROC  
 Primary platinum-refractory 60 (6.6) 
 Primary platinum-resistant 223 (24.7) 
 Secondary platinum-refractory 88 (9.7) 
 Secondary platinum-resistant 169 (18.7) 
 Potentially platinum sensitive ≥3a 363 (40.2) 
ECOG performance status  
 0 306 (33.9) 
 1 498 (55.1) 
 2 92 (10.2) 
 3 7 (0.8) 
Lines of previous treatment for ovarian cancer  
 1 178 (19.7) 
 2 336 (37.2) 
 3 203 (22.5) 
 ≥4 (maximum 10) 186 (11.5) 
Response to most recent line  
 Complete response 115 (12.8) 
 Progressive disease 362 (40.2) 
 Partial response 246 (27.3) 
 Stable disease 150 (16.7) 
 Unknown (not assessed) 27 (3.0) 
Clinician rating of symptoms at baseline  
 Cancer-related symptoms 650 (72.1) 
 Symptomatic ascites  202 (22.4) 
 Symptoms of cramping abdominal pain, or 
intermittent or incomplete bowel obstruction  
369 (40.9) 
Reasons for planned chemotherapy  
 Symptom control or palliation 635 (70.6) 
 If asymptomatic, to delay the development of 
symptoms 
278 (35.9) 
 Rising CA125 534 (63.0) 
 Radiological evidence of progression 602 (76.3) 
a. Potentially platinum sensitive disease but had 3 or more prior lines of chemotherapy. 
Abbreviations: MOST, Measure of Ovarian Symptoms and Treatment; PRROC, platinum resistant or refractory 
recurrent ovarian cancer. 
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Table 2. Revision of the MOST version 1 (35 items) to MOST version 2 (24 items) 
MOSTv1 symptoms and 
problems* 
Attributiona-e Changef MOSTv2g Reason, if excluded 
Abdominal pain, discomfort and/or 
cramps 
ROCa I MOST-Abdo  
Abdominal swelling, bloating 
and/or fullness 
ROCa I MOST-Abdo  
Fatigue (tiredness) ROC/Chemo b W MOST-DorT  
Trouble eating ROC/Chemo b W MOST-DorT  
Indigestion ROC/Chemob W MOST-DorT  
Nausea ROC/Chemob W MOST-DorT  
Vomiting ROC/Chemob W MOST-DorT  
Diarrhoea ROC/Chemob W MOST-DorT  
Constipation ROC/Chemob W MOST-DorT  
Shortness of breath ROC/Chemob W MOST-DorT  
Difficulty swallowing ROC/Chemob W MOST-DorT  
Trouble sleeping ROC/Chemob I DorT or Single?  
Bladder problems ROC/Chemob I DorT or Single?  
Pain (all/anywhere) ROC/Chemob I Excluded Too general, redundant 
(r=0.66 abdominal pain) 
Poor appetite (or feeling full 
quickly) 
ROC/Chemob 0 Excluded Redundant (r=0.78 trouble 
eating, r=0.70 loss of appetite) 
Loss of appetite ROC/Chemob W Excluded Redundant (r=0.73 trouble 
eating, r=0.79 poor appetite) 
Leg swelling ROC/Chemob 0 Excluded Uncommon, didn't change 
Trouble concentrating ROC/Chemob I Excluded Consequence not symptom, 
too general, R (r=0.64 anxiety) 
*Problems doing what I wanted ROC/Chemob W Excluded Consequence not symptom 
*Problems for my family or friends ROC/Chemob I Excluded Consequence not symptom 
Altered sense of taste Chemoc W MOST-Chemo  
Sore mouth or throat Chemoc W MOST-Chemo  
Hair loss Chemoc W MOST-Chemo  
Skin rash Chemoc W MOST-Chemo  
Numbness or pins and needles Chemoc W MOST-Chemo  
Sore hands and feet Chemoc W MOST-Chemo  
*Problems taking tablets   W Excluded Consequence not symptom  
*Problems with needles or 
injections 
  I Excluded Consequence not symptom  
*Inconvenience of treatment    W Excluded Consequence not symptom  
*Thought of actually having 
treatment 
  I Excluded Consequence not symptom  
Anxiety (feeling worried) Psychd I MOST-Psych  
Depression (feeling sad) Psychd I MOST-Psych  
Physical well-being Wellbeinge I MOST-
Wellbeing 
 
Emotional wellbeing   Wellbeinge I MOST-
Wellbeing 
 
Overall wellbeing Wellbeinge I MOST-
Wellbeing 
 
3 
 
a Physical symptoms most likely due to ROC and not chemotherapy. 
b Physical symptoms most likely due to chemotherapy and not ROC. 
c Physical symptoms reasonably likely due to ROC and/or chemotherapy. 
d Psychological symptoms. 
e Global wellbeing (physical, emotional and overall). 
f Shaded cells indicate correlations ≥ 0.50. 
f Direction of change from baseline to cycle 3: I = improved, W = worsened, 0 = zero change 
g MOSTv2 scoring rules yield five multi-item scales: MOST-Abdo, MOST-DorT, MOST-Chemo, MOST-Psych, 
MOST-Wellbeing, with two items (trouble sleeping, bladder problems) to either be included in MOST-DorT or 
retained as single items, pending psychometric performance of nine and eleven item versions (MOST-DorT-9, 
MOST-DorT-11). 
Abbreviations: MOST, Measure of Ovarian Symptoms and Treatment; ROC, recurrent ovarian cancer 
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Table 3. Internal consistency (Cronbach alpha) and convergent and divergent validity (Spearman 
correlationa of MOST domains with each other and EORTC, FACT-O and FOSI domains) at baseline 
(N=903) 
Domains 
MOST-
Abdoa 
MOST-
Chemob 
MOST-
DorT-9c 
MOST-
DorT-11c 
MOST-
Psychd 
MOST-
Wellbeinge 
Internal consistency 0.80 0.84 0.84 0.65 0.86 0.91 
Convergent validity       
 EORTC       
 OV28-Abdo 0.77f,g 0.28 0.70 0.71  0.26 -0.42 
 OV28-Chemo 0.25 0.60 0.38 0.40 0.23 -0.30 
 OV28-Peripheral neuropathy 0.18 0.67 0.27 0.28 0.18 -0.24 
 C30-Fatigue 0.52 0.37 0.69 0.70 0.37 -0.59 
 C30-Nausea/vomiting 0.43 0.23 0.63 0.61 0.22 -0.33 
 C30-Diarrhea 0.23 0.15 0.32 0.31 0.14 -0.15 
 C30-Constipation 0.35 0.22 0.45 0.44 0.17 -0.26 
 C30-Shortness of breath 0.33 0.25 0.49 0.47 0.18 -0.30 
 C30-Appetite 0.40 0.22 0.59 0.58 0.22 -0.42 
 C30-Emotional functioning -0.34 -0.22 -0.41 -0.45 -0.71 0.55 
 C30-Global Health/QOL -0.50 -0.33 -0.62 -0.62 -0.39 0.66 
 FACT-O       
 Ovarian Cancer Additional 
   concerns 
-0.53 -0.35 -0.64 -0.63 -0.34 0.54 
 Trial Outcome Index -0.56 -0.42 -0.71 -0.72 -0.48 0.70 
 Emotional wellbeing -0.22 -0.18 -0.27 -0.30 -0.72 0.48 
 FACT-O total -0.48 -0.39 -0.63 -0.65 -0.59 0.70 
 FOSI       
 FOSI-8 -0.72 -0.34 -0.76 -0.77 -0.47 0.61 
 FOSI-15h -0.63 -0.43 -0.73 -0.75 -0.53 0.68 
Divergent       
 MOST-Chemo 0.26      
 MOST-DorT-9 0.68 0.40     
 MOST- DorT-11 0.69 0.40 0.98    
 MOST-Psych 0.28 0.25 0.35 0.39   
 MOST-Wellbeing -0.43 -0.30 -0.58 -0.59 -0.57  
a Physical symptoms most likely due to ROC and not chemotherapy. 
b Physical symptoms most likely due to chemotherapy and not ROC. 
c Physical symptoms reasonably likely due to ROC and/or chemotherapy. 
d Psychological symptoms. 
e Global wellbeing (physical, emotional and overall). 
f Shaded cells indicate correlations ≥ 0.50. 
f Shaded cells indicate correlations ≥ 0.50. 
g Bolding indicates correlations between MOST and scales from other patient-related outcome measures with 
similar content or intent. 
h FOSI-15 contains 15 of the 18 items in FOSI-18, which was published after GICG-SBS commenced. We used 
the 15 items available in FACT-O to create FOSI-15 as the closest possible approximation to FOSI-15. 
Abbreviations: MOST, Measure of Ovarian Symptoms and Treatment;  EORTC, European Organisation for 
Research and Treatment of Cancer; FACT-O, Functional Assessment of Cancer Therapy-Ovarian; FOSI, 
FACT Ovarian Symptom Index; QOL, quality of life, ROC, recurrent ovarian cancer.
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Table 4. Discriminative validity for MOST multi-item scales * 
  
Expect poorer 
outcomes 
 
Expect better 
outcomes 
    
Scaled subscale score Anchor n Mean (SD) n Mean (SD) 
Difference in means 
(95% confidence limits) P 
Effect size (95% 
confidence limits) 
Baseline         
MOST-Abdo  Cancer symptoms (yes/no) 643 40.8 (27.46) 249 16.7 (19.53) 24.04 (20.30, 27.77) <0.001 1.00 (0.84, 1.16) 
 Ascites  (yes/no) 200 55.3 (26.67) 693 27.9 (24.78) 27.36 (23.39, 31.34) <0.001 0.96 (0.79, 1.13) 
 Abdominal pain or bowel 
obstruction  (yes/no)a 
364 45.3 (27.14) 529 26.4 (25.31) 18.90 (15.42, 22.38) <0.001 0.73 (0.59, 0.87) 
 ECOG: 2-3 vs 0-1b 98 45.4 (28.57) 795 32.7 (27.24) 12.74 (6.99, 18.50) <0.001 0.42 (0.21, 0.64) 
MOST-DorT-9 Cancer symptoms (yes/no) 638 23.2 (17.28) 250 11.9 (13.24) 11.27 (8.90, 13.65) <0.001 0.82 (0.67, 0.98) 
 Ascites  (yes/no) 200 30.2 (19.75) 689 17.1 (14.88) 13.13 (10.59, 15.67) <0.001 0.77 (0.60, 0.94) 
 Abdominal pain or bowel 
obstruction  (yes/no)a 
361 25.6 (18.39) 528 16.2 (14.84) 9.43 (7.24, 11.63) <0.001 0.59 (0.46, 0.73) 
 ECOG: 2-3 vs 0-1b 97 32.9 (18.52) 792 18.4 (16.13) 14.46 (11.00, 17.93) <0.001 0.85 (0.62, 1.09) 
 CTC-AE score >medianc 429 23.8 (17.42) 458 16.4 (15.57) 7.39 (5.21, 9.56) <0.001 0.53 (0.39, 0.66) 
MOST-DorT-11 Cancer symptoms  (yes/no) 638 23.5 (16.28) 250 12.5 (12.78) 11.02 (8.77, 13.28) <0.001 0.85 (0.69, 1.00) 
 Ascites  (yes/no) 200 29.3 (18.58) 689 17.8 (14.38) 11.51 (9.07, 13.94) <0.001 0.71 (0.54, 0.88) 
 Abdominal pain or bowel 
obstruction (yes/no)a 
361 25.7 (17.19) 528 16.7 (14.31) 8.96 (6.88, 11.04) <0.001 0.60 (0.46, 0.73) 
 ECOG: 2-3 vs 0-1b 97 32.0 (17.23) 792 19.0 (15.42) 13.09 (9.79, 16.39) <0.001 0.81 (0.57, 1.04) 
 CTC-AE score >medianc 429 23.7 (16.27) 458 17.2 (15.17) 6.47 (4.40, 8.54) <0.001 0.48 (0.35, 0.62) 
MOST-Psych Cancer symptoms  (yes/no) 645 34.1 (27.07) 250 32.2 (27.48) 1.92 (-2.05, 5.90) 0.18 0.10 (-0.05, 0.25) 
 Ascites  (yes/no) 201 34.8 (27.39) 695 33.2 (27.11) 1.56 (-2.71, 5.83) 0.39 0.07 (-0.09,0.23) 
 Abdominal pain or bowel 
obstruction  (yes/no)a 
366 35.5 (28.13) 530 32.2 (26.43) 3.33 (-0.29, 6.94) 0.096 0.12 (-0.02,0.25) 
 ECOG: 2-3 vs 0-1b 97 36.5 (31.13) 799 33.2 (26.65) 3.28 (-2.45, 9.02) 0.60 0.06 (-0.15,0.27) 
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Expect poorer 
outcomes 
 
Expect better 
outcomes 
    
Scaled subscale score Anchor n Mean (SD) n Mean (SD) 
Difference in means 
(95% confidence limits) P 
Effect size (95% 
confidence limits) 
MOST Well-being index  Cancer symptoms  (yes/no) 629 55.0 (19.83) 247 64.5 (18.16) -9.50 (-12.36, -6.65) <0.001 -0.49 (-0.64, -0.34) 
Ascites  (yes/no) 195 52.0 (21.57) 682 59.3 (19.00) -7.29 (-10.41, -4.17) <0.001 -0.37 (-0.53, -0.21) 
 Abdominal pain or bowel 
obstruction  (yes/no)a  
357 53.6 (20.41) 520 60.5 (18.93) -6.85 (-9.48, -4.21) <0.001 -0.35 (-0.49, -0.21) 
 ECOG: 2-3 vs 0-1b 94 45.8 (21.74) 783 59.1 (19.10) -13.34 (-17.49, -9.18) <0.001 -0.69 (-0.92, -0.45) 
Pre-cycle 3         
MOST-DorT-9 CTC-AE score >medianc 238 28.9 (18.65) 435 16.9 (14.43) 11.96 (9.42, 14.50) <0.001 0.75 (0.58, 0.91) 
MOST-DorT-11 CTC-AE score >medianc 238 27.6 (17.52) 435 17.2 (14.00) 10.41 (7.98, 12.83) <0.001 0.69 (0.52, 0.85) 
MOST-Chemo CTC-AE score >mediand 305 24.6 (17.10) 370 16.9 (14.68) 7.73 (5.32, 10.13) <0.001 0.52 (0.36, 0.67) 
a Clinician-rated symptoms of cramping abdominal pain or intermittent/incomplete bowel obstruction 
b Performance status: poor [ECOG 2-3] vs good [ECOG 0-1] 
c Score includes: nausea, vomiting, diarrhea, constipation, anorexia, fatigue (representing 6 of the 9–11 MOST-DorT items)  
d Score includes: neuropathy-sensory, hand-foot syndrome, alopecia, erythema, mucositis/stomatitis (representing 5 of the 6 MOST-Chemo items) 
Abbreviations: MOST, Measure of Ovarian Symptoms and Treatment; ECOG, Eastern Cooperative Oncology Group performance status; CTC-AE, Common Terminology 
Criteria for Adverse Events.
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Table 5. Mean change from baseline to pre-cycle 3 of chemotherapy for the MOSTv2 multi-item scales, 
grouped by clinician-rated baseline abdominal symptoms and type of recurrent ovarian cancer 
MOST multi-item 
scale n Mean (95% CL)a Pb n Mean (95% CL)a Pb Pc 
Baseline 
abdominal 
symptomsd  Yes   No   
MOST-Abdo 249 -11.1 (-14.9, -7.29) <0.001 407 -0.59 (-2.90, 1.73) 0.62 <0.001 
MOST-Chemo  252 6.46 (4.34, 8.58) <0.001 412 7.01 (5.42, 8.60) <0.001 0.68 
MOST-DorT-9 247 0.56 (-1.81, 2.92) 0.64 409 5.02 (3.55, 6.49) <0.001 <0.001 
MOST- DorT-11 247 -0.08 (-2.33, 2.16) 0.94 409 4.05 (2.71, 5.38) <0.001 <0.001 
MOST-Psych 253 -4.11 (-7.24, -0.98) 0.01 414 -2.78 (-4.89, -0.67) 0.01 0.47 
MOST-Wellbeing  233 -0.64 (-3.48, 2.21) 0.60 389 1.79 (-0.15, 3.72) 0.07 0.15 
ROC typee  PRROC   PPS≥3   
MOST-Abdo 375 -4.84 (-7.65, -2.03) <0.001 281 -4.23 (-7.31, -1.15) 0.007 0.78 
MOST-Chemo  380 4.49 (2.86, 6.12) <0.001 284 9.90 (7.93, 11.87) <0.001 <0.001 
MOST-DorT-9 376 2.35 (0.65, 4.05) 0.01 280 4.67 (2.71, 6.64) <0.001 0.08 
MOST- DorT-11 376 1.61 (0.02, 3.20) 0.05 280 3.67 (1.86, 5.49) <0.001 0.09 
MOST-Psych 380 -4.12 (-6.53, -1.71) <0.001 287 -2.18 (-4.76, 0.41) 0.10 0.29 
MOST-Wellbeing  351 0.38 (-1.68, 2.45,) 0.71 271 1.52 (-1.05, 4.08) 0.25 0.49 
 
a  Negative change indicates improvement, positive change indicates worsening (the direction of the MOST-
Wellbeing scale has been reversed so it can be interpreted consistently with the MOST symptom scales). 
b Paired t test for change over time within a group. 
c 2-sample t test for difference between groups in change over time. 
d Clinician-rated symptoms of cramping abdominal pain or intermittent or incomplete bowel obstruction. 
e PRROC or potentially platinum sensitive ROC with ≥3 lines of prior chemotherapy (PPS≥3). 
Abbreviations: MOST, Measure of Ovarian Symptoms and Treatment; ROC, recurrent ovarian cancer; PRROC, 
platinum-resistant or refractory ROC; PPS, potentially platinum sensitive ROC. 
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Table 6. Responsiveness to change in ovarian cancer symptoms 
Group 
expected to 
change Experienced symptoms at baseline 
Experienced improvement with 
chemotherapy n 
Mean 
change 
SD 
(change) P 
Effect size (95% 
confidence limits) 
Definition 1 Scores GE 40 on MOST-Abdo scale 
(mean of 4 or more on items 4 and 5) 
Abdo change items (4 and 5):  
average change of 1 or 1.5 
57 -43.1 21.4 <0.001 -2.01 (-2.52, -1.51) 
Definition 2 Rated by clinicians as having 
abdominal symptoms 
Scored 1 (much better) on the 
global wellbeing item (18) 
48 -26.3 25.9 <0.001 -1.02 (-1.39, -0.64) 
 
Figure legends and footnotes: 
 
Fig. 1 Baseline prevalence of physical symptoms and other treatment related problems* assessed by 
the MOST version 1a 
* Treatment-related problems 
  
Fig. 2 Mean change from baseline for each MOSTv1 item (n=685 who completed MOST prior to Cycle 
3 chemotherapy)  
 
Fig. 3 Boxplots of change scores for each MOST multi-item scale grouped by patient-rated change 
category from the most relevant MOST-Change item 
 
Fig. A Boxplots for MOST Disease or Treatment (MOST-DorT) items corresponding to Common 
Terminology for Adverse Events (CTC-AE) Nausea, Vomiting, Diarrhea, Constipation, Anorexia, 
Fatigue, plotted by CTC-AE grade 
 
Fig. B Boxplots for MOST items caused solely by chemotherapy (MOST-Chemo) corresponding to 
Common Terminology for Adverse Events (CTC-AE) Neuropathy – sensory, Hand-foot syndrome, 
Alopecia, Erythema, Mucositis/Stomatitis, plotted by CTC-AE grade 
 
Figure legends Click here to download Figure Figure legend.docx 
Figure 1 Click here to download Figure Fig 1.tif 
Figure 2 Click here to download Figure Fig 2.tif 
Figure 3 Click here to download Figure Fig 3.tif 
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Table A. Internal consistency (Cronbach alpha) and convergent validity (Spearman correlation of MOST 
domains with EORTC, FACT-O and FOSI domains) at pre-cycle 3 (N=685)  
 
MOST-
Abdoa 
MOST-
Chemob 
MOST-
DorT-9c 
MOST-
DorT-11c 
MOST-
Psychd 
MOST-
Wellbeinge 
Internal consistency 0.82 0.84 0.85 0.66 0.90 0.95 
Convergent validity       
EORTC       
 OV28-Abdo 0.75f,g 0.32 0.62 0.64 0.41 -0.40 
 OV28-Chemo 0.32 0.60 0.39 0.43 0.32 -0.31 
 OV28-Peripheral neuropathy 0.27 0.54 0.32 0.33 0.29 -0.25 
 C30-Fatigue 0.45 0.35 0.64 0.64 0.46 -0.58 
 C30-Nausea/vomiting 0.32 0.21 0.52 0.49 0.23 -0.28 
 C30-Diarrhea 0.22 0.12 0.27 0.26 0.13 -0.15 
 C30-Constipation 0.33 0.19 0.35 0.36 0.22 -0.21 
 C30-Shortness of breath 0.33 0.29 0.47 0.47 0.30 -0.35 
 C30-Appetite 0.40 0.30 0.63 0.61 0.36 -0.46 
 C30-Emotional functioning -0.38 -0.31 -0.45 -0.49 -0.75 0.57 
 C30-Global health/QOL -0.42 -0.32 -0.56 -0.57 -0.48 0.68 
FACT-O       
 Ovarian Cancer Additional    
   concerns 
-0.56 -0.37 -0.62 -0.62 -0.50 0.59 
 Trial Outcome Index -0.57 -0.41 -0.70* -0.71* -0.62 0.74 
 Emotional wellbeing -0.36 -0.21 -0.38 -0.41 -0.74* 0.59 
 FACT-O total -0.53 -0.37 -0.63 -0.65 -0.69 0.76* 
FOSI       
 FOSI-8 -0.70 -0.39 -0.72 -0.73 -0.60 0.64 
 FOSI-152 -0.62 -0.45 -0.70 -0.72 -0.67 0.72 
MOST       
 MOST-Chemo 0.35      
 MOST-DorT-9 0.67 0.50     
 MOST- DorT-11 0.69 0.52 0.98    
 MOST-Psych 0.44 0.39 0.52 0.56   
 MOST-Wellbeing -0.43 -0.33 -0.59 -0.61 -0.67  
a Physical symptoms most likely due to ROC and not chemotherapy. 
b Physical symptoms most likely due to chemotherapy and not ROC. 
c Physical symptoms reasonably likely due to ROC and/or chemotherapy. 
d Psychological symptoms. 
e Global wellbeing (physical, emotional and overall). 
f Shaded cells indicate correlations ≥ 0.50. 
g Bolding indicates correlations between MOST and scales from other patient-related outcome measures with 
similar content or intent. 
h FOSI-15 contains 15 of the 18 items in FOSI-18, which was published after GICG-SBS commenced. We used 
the 15 items available in FACT-O to create FOSI-15 as the closest possible approximation to FOSI-15. 
Abbreviations: QOL, quality of life; ROC, recurrent ovarian cancer. 
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Fig.	A	Boxplots	for	MOST	Disease	or	Treatment	(MOST-DorT)	items	corresponding	to	CTC-AE	Nausea,	
Vomiting,	Diarrhea,	Constipation,	Anorexia,	Fatigue,	plotted	by	CTC-AE	grade	
 
 
  
 4 
Fig.	B	Boxplots	for	MOST	items	caused	solely	by	chemotherapy	(MOST-Chemo)	corresponding	to	
CTC-AE	Neuropathy	–	sensory,	Hand-foot	syndrome,	Alopecia,	Erythema,	Mucositis/Stomatitis,	
plotted	by	CTC-AE	grade	
 
